	US 12,433,289 B2
	Compositions and methods of cryopreserving cells
Lan Cao, Cambridge, MA (US); Hui-Hsin Chang, Cambridge, MA (US); Jianxin Hu, Cambridge, MA (US); Xi Shi, Cambridge, MA (US); and Yutaka Nishimoto, Shonan (JP)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Jan. 20, 2021, as Appl. No. 17/153,458.
Claims priority of provisional application 62/964,074, filed on Jan. 21, 2020.
Prior Publication US 2021/0315198 A1, Oct. 14, 2021
Int. Cl. A01N 1/126 (2025.01); A01N 1/125 (2025.01)

CPC A01N 1/125 (2025.01) [A01N 1/126 (2025.01)]

22 Claims

1. A composition comprising:

mammalian immune cells that are primary cells or derived from induced pluripotent stem cells; and

a cryopreservation medium comprising: about 5 w/v % dimethyl sulfoxide (DMSO), between about 0.25 w/v % and 5 w/v % disaccharide, and human serum albumin (HSA), wherein the disaccharide is sucrose.